Patients with metabolic syndrome have significantly worse hospitalization and mortality rates due to COVID-19. Hypertension, diabetes, and obesity are common comorbidities associated with metabolic syndrome, as described in a new study published in the peer-reviewed journal Metabolic Syndrome and Related Disorders.
“Our results demonstrate that patients with metabolic syndrome were 77% more likely to be hospitalized, 56% more likely to be admitted to the intensive care unit, and 81% more likely to die from COVID-19, according to Sangeeta Kashyap, MD, from the Cleveland Clinic, and coauthors. “Obesity, hyperglycemia, dyslipidemia, and hypertension are modifiable components of metabolic syndrome that would reduce morbidity and mortality of COVID-19,” conclude the investigators.
“This paper is a timely reminder of the need to appreciate individual risk factors when assessing outcomes of COVID-19—and that obesity is probably the most important (and modifiable) risk factor that explains the increase in risk. For example, the presence of metabolic syndrome doubled the death rate from 3% to 6%. Half of all patients with metabolic syndrome were hospitalized—in contrast to 25% of those without metabolic syndrome,” says Dr. Adrian Vella, Editor-in-Chief of Metabolic Syndrome and Related Disorders and Professor, Mayo Clinic College of Medicine, Rochester, MN.
Shannon Wu et al, Impact of Metabolic Syndrome on Severity of COVID-19 Illness, Metabolic Syndrome and Related Disorders (2022). DOI: 10.1089/met.2021.0102
Mary Ann Liebert, Inc
Impact of metabolic syndrome on severity of COVID-19 illness (2022, January 11)
retrieved 11 January 2022
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.